PDF icon Download PDF
Int J Sports Med 2004; 25(1): 20-26
DOI: 10.1055/s-2003-45227
Physiology & Biochemistry
© Georg Thieme Verlag Stuttgart · New York

Hypertrophic Cardiomyopathy -Sports-Related Aspects of Diagnosis, Therapy, and Sports Eligibility

A. A.  Hipp1 , H. C.  Heitkamp1 , K.  Röcker2 , H. H.  Dickhuth2
  • 1Medical Clinic, Department of Sports Medicine, University of Tübingen, Germany
  • 2Department of Rehabilitation, Prevention and Sports Medicine, University of Freiburg, Germany
Further Information

Publication History

Accepted after revision: April 5, 2003

Publication Date:
29 January 2004 (online)

Also available ateRef
   Permissions and Reprints
Preview

Abstract

Hypertrophic cardiomyopathy (HCM) is one of the primary causes of sudden cardiac death in athletes < 35 years of age. The highest risk of sudden cardiac death is associated with syncope, early age, extreme ventricular hypertrophy, ventricular tachycardia, and a family history of sudden death. The relative risk in competitive sports is unknown. Usually, sports eligibility is rejected. However, some athletes with HCM tolerate extreme athletic lifestyles without complications. Sports-related aspects of diagnosis, therapy, and sports eligibility are presented, and discussed. Two case reports are presented: a 20-year-old professional soccer player and a 66-year-old long-distance runner. Athletes with HCM should not participate in most competitive sports with the possible exception of those of low dynamic and low static intensity. Participation in low to moderate athletic activities may be allowed in selected patients without risk factors and > 35 years of age.

Key words

Hypertrophic cardiomyopathy - prevention - sports eligibility - sudden cardiac death

References

  • 1 Burke A P, Farb A, Virmani R, Goodin J, Smialek J E. Sports related and non-sports related sudden cardiac death in young adults.  Am Heart J. 1991;  121 568 - 575
    CrossrefPubMedSearch in Google Scholar
  • 2 Cecchi F, Maron B, Epstein S. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest.  J Am Coll Cardiol. 1989;  13 1283 - 1288
    PubMedSearch in Google Scholar
  • 3 Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes.  N Engl J Med. 1998;  339 364 - 369
    CrossrefPubMedSearch in Google Scholar
  • 4 Dickhuth H H, Röcker K, Hipp A, Heitkamp H C, Keul J. Echocardiographic findings in endurance athletes with hypertrophic non-obstructive cardiomyopathy (HNCM) compared to non-athletes with HNCM and to physiological hypertrophy (athlete's heart).  Int J Sports Med. 1994;  15 273 - 277
    PubMedSearch in Google Scholar
  • 5 Elliott P M, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon N G, McKenna W J. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.  J Am Coll Cardiol. 2000;  36 2212 - 2218
    CrossrefPubMedSearch in Google Scholar
  • 6 Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long-term follow up of the first series of 25 patients.  Heart. 2000;  83 326 - 331
    CrossrefPubMedSearch in Google Scholar
  • 7 Geisterfer-Lowrance A A, Christe M, Conner D A, Ingwall J S, Schoen F J, Seidman C E, Seidman J G. A mouse model of familial hypertrophic cardiomyopathy.  Science. 1996;  272 731 - 734
    PubMedSearch in Google Scholar
  • 8 Hagège A A, Dubourg O, Desnos M, Mirochnik R, Isnard G, Bonne G, Carrier L, Guicheney P, Bouhour J B, Schwartz K, Komajda M. Familial hypertrophic cardiomyopathy - cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy.  Eur Heart J. 1998;  19 490 - 499
    CrossrefPubMedSearch in Google Scholar
  • 9 International Federation of Sports Medicine (FIMS) .Scientific Committee Recommendations for medical evaluation and sports participation in athletes with a family history of sudden cardiac death. In: International Sports Medicine Directory. Human Kinetics 2001: 247-248
    Search in Google Scholar
  • 10 Lim D S, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R, Marian A J. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.  Circulation . 2001;  103 789 - 791
    PubMedSearch in Google Scholar
  • 11 Malik M. Heart rate variability. Standards of measurement, physiological interpretation and clinical use.  Circulation. 1996;  93 1043 - 1065
    Search in Google Scholar
  • 12 Marian A, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy.  J Mol Cell Cardiol. 2001;  33 655 - 670
    CrossrefPubMedSearch in Google Scholar
  • 13 Maron B J. Hypertrophic cardiomyopathy - a systematic review.  J Am Med Ass. 2002;  287 1308 - 1320
    CrossrefPubMedSearch in Google Scholar
  • 14 Maron B J, Bonow R O, Cannon R O, Leon M B, Epstein S E. Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy.  N Engl J Med. 1987;  316 844 - 852
    PubMedSearch in Google Scholar
  • 15 Maron B J, Casey S A, Poliac L C, Gohman T E, Almquist A K, Aeppli D M. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort.  J Am Med Ass. 1999;  281 650 - 655
    CrossrefPubMedSearch in Google Scholar
  • 16 Maron B J, Cecchi F, McKenna W J. Risk factors and current status of risk stratification profiles for sudden cardiac death in patients with hypertrophic cardiomyopathy.  Br Heart J. 1994;  72 (suppl) 14 - 18
    PubMedSearch in Google Scholar
  • 17 Maron B J, Epstein S E, Roberts W C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries.  Am J Cardiol. 1979;  43 1086 - 1102
    CrossrefPubMedSearch in Google Scholar
  • 18 Maron B J, Fananapazir L. Sudden cardiac death in hypertrophic cardiomyopathy.  Circulation. 1992;  85 (suppl 1) 57 - 63
    PubMedSearch in Google Scholar
  • 19 Maron B J, Isner J M, McKenna W J. Task Force 3: Hypertrophic cardiomyopathy, myocarditis and other myocardial diseases and mitral valve prolapse.  J Am Coll Cardiol. 1994;  24 880 - 882
    PubMedSearch in Google Scholar
  • 20 Maron B J, Klues H G. Surviving competitive athletics with hypertrophic cardiomyopathy.  Am J Cardiol. 1994;  73 1098 - 1104
    CrossrefPubMedSearch in Google Scholar
  • 21 Maron B J, Moller J H, Seidman C E, Vincent G M, Dietz H C, Moss A J, Towbin J A, Sondheimer H M, Pyeritz R E, McGee G, Epstein A E. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long QT-syndrome, and Marfan syndrome: a statement for healthcare professionals from the councils on clinical cardiology, cardiovascular disease in the young, and basic science, American Heart Association.  Circulation. 1998;  98 1460 - 1471
    CrossrefPubMedSearch in Google Scholar
  • 22 Maron B J, Nishimura R A, McKenna W J, Rakowski H, Josephson M E, Kieval R S. Assessment of permanent dual chamber pacing as a treatment for drug refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-Pathy).  Circulation. 1999;  99 2927 - 2933
    PubMedSearch in Google Scholar
  • 23 Maron B J, Roberts W C, Epstein S E. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients.  Circulation. 1982;  67 1388 - 1394
    PubMedSearch in Google Scholar
  • 24 Maron B J, Shen W K, Link M S, Epstein A E, Almquist A K, Daubert J P, Bardy G H, Favale S, Rea R F, Boriani G, Ill M E, Spirito P. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.  N Engl J Med. 2000;  342 365 - 373
    CrossrefPubMedSearch in Google Scholar
  • 25 Maron MS, Olivotto I, Betocchi S, Casey S A, Lesser J R, Losi M A, Cecchi F, Maron B J. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy.  N Engl J Med. 2003;  348 295 - 303
    CrossrefPubMedSearch in Google Scholar
  • 26 McKenna W J, Camm A J. Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk.  Circulation. 1989;  80 1489 - 1492
    PubMedSearch in Google Scholar
  • 27 McKenna W J, Coccolo F, Elliott P M. Genes and disease expression in hypertrophic cardiomyopathy.  Lancet. 1998;  352 1162 - 1163
    CrossrefPubMedSearch in Google Scholar
  • 28 McKenna W J, Oakley C M, Krikler D M, Goodwin J F. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.  Br Heart J. 1985;  53 412 - 416
    PubMedSearch in Google Scholar
  • 29 Mitchell J H, Haskel W L, Raven P B. Classification of sports.  J Am Coll Cardiol. 1994;  24 864 - 866
    PubMedSearch in Google Scholar
  • 30 Mohiddin S A, Begley D, Shih J, Fananapazir L. Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease.  J Am Coll Cardiol. 2000;  36 2270 - 2278
    CrossrefPubMedSearch in Google Scholar
  • 31 Momiyama Y, Hartikainen J, Nagayoshi H, Albrecht P, Kautzner J, Saumarez R C, McKenna W J, Camm A J. Exercise-induced T-wave alternans as a marker of high risk in patients with hypertrophic cardiomyopathy.  Japn Circ J. 1997;  61 650 - 656
    PubMedSearch in Google Scholar
  • 32 Murda’h M, McKenna W J, Camm A J. Repolarization alternans: Techniques, mechanisms, and cardiac vulnerability.  Pace. 1997;  20 2641 - 2657
    PubMedSearch in Google Scholar
  • 33 Nagueh S, Bachinski L, Meyer D, Hill R, Zoghbi W A, Tam J W, Quinones M A, Roberts R, Marian A J. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy.  Circulation. 2001;  104 128 - 130
    CrossrefPubMedSearch in Google Scholar
  • 34 Olivotto I, Montereggi A, Mazzuoli F, Cecchi F. Clinical utility and safety of exercise testing in patients with hypertrophic cardiomyopathy.  G Ital Cardiol. 1999;  29 11 - 19
    PubMedSearch in Google Scholar
  • 35 Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose β-adrenoceptor antagonist treatment.  J Am Coll Cardiol. 1999;  34 1813 - 1822
    CrossrefPubMedSearch in Google Scholar
  • 36 Pinsky D J, Sciacca R R, Steinberg J S. QT-Dispersion as a marker of risk in patients awaiting heart transplantation.  J Am Coll Cardiol. 1997;  29 1576 - 1584
    CrossrefPubMedSearch in Google Scholar
  • 37 Raschka C, Parzeller M, Kind M, Banzer W. Organpathologische Ursachen des akuten Sporttodes in Deutschland, Österreich und der deutschsprachigen Schweiz.  Deutsch Z Sportmed. 1998;  49 157 - 160
    PubMedSearch in Google Scholar
  • 38 Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part I.  Circulation. 2001;  104 2113 - 2116
    PubMedSearch in Google Scholar
  • 39 Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part II.  Circulation. 2001;  104 2249 - 2252
    PubMedSearch in Google Scholar
  • 40 Spirito P, Maron B J. Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy.  J Am Coll Cardiol. 1999;  33 1071 - 1075
    CrossrefPubMedSearch in Google Scholar
  • 41 Spirito P, Seidman C E, McKenna W J, Maron B J. The management of hypertrophic cardiomyopathy.  N Engl J Med. 1997;  336 775 - 785
    CrossrefPubMedSearch in Google Scholar
  • 42 Tabib A, Miras A, Taniere P, Loire R. Undetected cardiac lesions cause unexpected sudden cardiac death during occasional sport activity - a report on 80 cases.  Eur Heart J. 1999;  20 900 - 903
    PubMedSearch in Google Scholar
  • 43 Varnava A, Baboonian C, Davison F, de Cruz L, Elliott P M, Davies M J, McKenna W J. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy.  Heart. 1999;  82 621 - 624
    PubMedSearch in Google Scholar
  • 44 Watkins H. Sudden death in hypertrophic cardiomyopathy.  N Engl J Med. 2000;  342 422 - 423
    CrossrefPubMedSearch in Google Scholar
  • 45 Yetman A T, McCrindle B W, MacDonald C, Freedom R M, Gow R. Myocardial bridging in children with hypertrophic cardiomyopathy - a risk factor for sudden death.  N Engl J Med. 1998;  339 1201 - 1209
    CrossrefPubMedSearch in Google Scholar

Dr. A. Hipp

Abteilung Sportmedizin, Medizinische Klinik, Universität Tübingen

Silcherstraße 5 · 72076 Tübingen · Germany ·

Phone: +49 7071 2986493

Fax: +49 7071 295162

Email: arno.hipp@med.uni-tuebingen.de